Open AccessRationale for dapagliflozin administration for the prevention of adverse outcomes in patients with heart failure with reduced ejection fraction. Expert consensus statement
Author(s) -
С Н Терещенко,
Marina Vladimirovna Shestakova,
Ф Т Агеев,
Г. Р. Галстян,
А. С. Галявич,
М. Г. Глезер,
И. В. Жиров,
Ю. А. Карпов,
Ж. Д. Кобалава,
С.Т. Мацкеплишвили
Publication year - 2020
Publication title -
rossijskij kardiologičeskij žurnal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.141
H-Index - 14
eISSN - 2618-7620
pISSN - 1560-4071
DOI - 10.15829/1560-4071-2020-3919
Subject(s) - medicine , ejection fraction , dapagliflozin , heart failure , statement (logic) , benzhydryl compounds , adverse effect , intensive care medicine , administration (probate law) , cardiology , diabetes mellitus , endocrinology , political science , type 2 diabetes , law , chemistry , epoxy , organic chemistry , bisphenol a